48th Annual ICAAC / IDSA 46th Annual Meeting<br>

Conference Reports for NATAP


ICAAC 48th Annual ICAAC / IDSA 46th Annual Meeting October 25-28, 2008 Washington, DC

	The New Antitubercular Drugs SQ109 and TMC207 Act Synergistically In Vitro to Kill M. tuberculosis - (01/17/09) Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis: effective and safe - (01/17/09) New CCR5 Drug PRO 140 Reduced Viral Load by 2 Logs With Single 10 mg Intravenous Dose; 5/5 patients with single 10 mg dose had >2 log reduction in viral load - (01/06/09) Perceptions of Care by HIV-Infected Women of Color in the United States - (12/15/08) Roles of Race, Drug Use & Health Insurance in Use of HAART Among HIV-Positive Women: 2002-2005 - (12/15/08) DELPHI: Safety, tolerability and efficacy of darunavir/ritonavir over 48 weeks in ARV treatment-experienced children and adolescents Final analysis (12/11/08) AIDS-Defining Conditions (ADCs) in the BENCHMRK -1 and -2 Trials: 48 Week Analysis (12/10/08) Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2 (12/10/08) Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV- Infected Patients Following 48 Weeks of Treatment (12/10/08) DOUBLING THE DOSE OF RALTEGRAVIR (RAL) DOES NOT INCREASE TROUGH LEVELS IN THE PRESENCE OF RIFAMPIN (RIF) (12/08/08) Omeprazole Increases Plasma Levels of Raltegravir (RAL) in Healthy Subjects (12/08/08) Raltegravir (RAL) Pharmacokinetics in Individuals with UGT1A11/1 and UGT1A128/28 Genotypes (12/08/08) Pharmacokinetic (PK) Evaluation of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects (12/08/08) Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2 (12/08/08) Performance Characteristics and Validation of the PhenoSense® Integrase Assay (12/02/08) Raltegravir Pharmacokinetics and Safety in Adolescents: Preliminary Results from IMPAACT P1066 (12/02/08) Validation of an Enhanced Sensitivity Trofile™ HIV-1 Co-receptor Tropism Assay (12/02/08) Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) (12/02/08) Chronic Hepatitis B Virus (HBV) Infection in the HIV Outpatient Study (HOPS), 1996-2006: Prevalence in the Era of Evolving Interventions (12/02/08) Continuous Antiretroviral Therapy Decreases Bone Mineral Density: Results from the SMART Study (11/24/08) Earlier Chance at HIV Diagnosis Probably Often Missed in Prison written by Mark Mascolini (11/12/08) Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants (11/12/08) Pharmacology at ICAAC-IDSA - The Maraviroc and Raltegravir Interaction: Do We Know How to Dose When Using These Two Important Agents? Written by Stephen Becker, MD (11/12/08) Summary from ICAAC/IDSA for Treatment Naïve patients written by Joseph J. Eron Jr. MD (11/12/08) HIV drug resistance at IDSA/ICAAC written by David Margolis, MD (11/12/08) Complications of HIV infection. A summary form the IDSA/ICAAC conference in Washington DC. written by Pablo Tebas (11/07/08) An enhanced assay to refine the use of CCR5 inhibitors - Written by David Margolis, MD (11/07/08) HbA1c Underestimates Plasma Glucose in People Taking Antiretrovirals - Written by Mark Mascolini - (11/06/08) Longer Antiretroviral Therapy Means Bigger Coronary Plaques - Written by Mark Mascolini - - (11/03/08) KS, NHL, and Encephalopathy Getting Diagnosed at Higher CD4 Counts in US Cohort - Written by Mark Mascolini - (11/03/08) Nonalcoholic Fatty Liver in One Third of Naval Center Patients With HIV - Written by Mark Mascolini - (11/03/08) Body Fat and Bone Changes After 96 Weeks of Fosamprenavir/Ritonavir - Written by Mark Mascolini - (11/03/08) Antiretrovirals at CD4 Counts Above 350 May Quell HCV-Related Liver Inflammation - Written by Mark Mascolini - (11/03/08) Limb and Trunk Fat Changes by Total Body DEXA After 96 Weeks of Treatment with Once-Daily (QD) Fosamprenavir Boosted with Either 100 mg or 200 mg of Ritonavir (/r) plus Abacavir (ABC)/lamivudine (3TC): COL100758 - (11/03/08) Comparative Analysis of HIV+ and HIV- Interaction with Testosterone on Bone Mineral Density - (11/03/08) HIV Infection and the Risk of Diabetes Mellitus - (11/03/08) CD4+ Cell Increases at 48 Weeks in the Maraviroc Treatment-naive MERIT Trial - (10/31/08) Adverse Event Profile of Maraviroc in Treatment-experienced Patients Infected with R5 HIV-1 - (10/31/08) Unremitting Kaposi Sarcoma in HIV infected patients with viral suppression on antiretrovirals - (10/31/08) Should Vitamin D Be Prescribed with Tenofovir/FTC? - (10/31/08) Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08) Substitution of Nevirapine (NVP) for Efavirenz (EFV) Toxicity in ACTG A5095 - (10/31/08) Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and rifabutin - (10/31/08) Treatment Response among HIV Patients Co-enrolled in the Etravirine (ETR) and Raltegravir (RAL) Expanded Access Programs (EAPs) at Kaiser Permanente - (10/31/08) Pharmacokinetics and pharmacodynamics of etravirine in treatment-experienced HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2 - (10/31/08) Renal Function after Use of Tenofovir as Part of the Initial ART Regimen - (10/31/08) Prevalence and Risk Factors of Chronic Kidney Disease in an HIV Infected Minority Urban Population - (10/31/08) A Phase II Safety and Efficacy Study of Bevirimat in Heavily Treatment-Experienced HIV+ Patients Identifies the Target Phase III Study Profile - (10/30/08) Low Vitamin D Tied to High Bone Marker Levels in Men Taking Tenofovir - Written by Mark Mascolini - (10/30/08) Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08) Pulmonary Hypertension Rate 5.5% in Antiretroviral-Treated US Navy Group - Written by Mark Mascolini - (10/30/08) Darunavir or Raltegravir in Rescue Regimen Raises Chance of Success 3 to 4 Times - Written by Mark Mascolini - (10/30/08) High Rash Rate in Healthy Volunteers Combining Raltegravir and Darunavir - Written by Mark Mascolini - (10/30/08) Did HIV Become More Virulent in First Decade of US Epidemic? - Written by Mark Mascolini - (10/30/08) Hospital Admission Rate Stays Higher for First 90 Days of HAART - Written by Mark Mascolini - (10/30/08) Doubled Risk of Failure After 1 Year Under 50 Copies in Women and Steady Blippers - Written by Mark Mascolini - (10/30/08) Long-Term Safety of Vicriviroc: out to 4 yrs (10/29/08) A Pharmacokinetic Study to Evaluate an Interaction between Maraviroc and Raltegravir in Healthy Adults (10/29/08) Pharmacokinetic (PK) Evaluation of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects (10/29/08) Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial (10/29/08) Single Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Naïve Patients: IMANI II - 96 Week Final Results (10/29/08) Darunavir Makes HIV Undetectable in Half of Heavily Pretreated Children - Written by Mark Mascolini - (10/28/08) Phase 2 Trial Confirms Baseline Mutation Risk With Maturation Inhibitor - Written by Mark Mascolini - (10/28/08) Lower CD4 Count With HIV Ups Risk of Anal Cancer in Case-Control Study - Written by Mark Mascolini - (10/28/08) Antiretroviral Therapy Lowers MRSA Risk 84% in US Cohort Study - Written by Mark Mascolini - (10/28/08) Antiretroviral Trial Strictures Make Outcomes Harder to Interpret in Clinic: HIV trials need patients with 'major illnesses or more advanced HIV disease' - Written by Mark Mascolini - (10/28/08) Lower Risk of Diabetes With HIV in US Veterans Affairs Cohort - Written by Mark Mascolini - (10/28/08) Characterization of Virologic Failure Over 96 Weeks by Drug Resistance and Antiviral Response in ART Naïve Patients Receiving Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) Each with Lopinavir/Ritonavir QD in the HEAT Study (10/28/08) The Impact of Tenofovir on Insulin Sensitivity and Lipids in Healthy Volunteers (10/28/08) Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTIs (10/28/08) RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients (10/28/08) Elvucitabine Phase II 48 Week Interim Results Show Safety and Efficacy Profiles Similar to Lamivudine in Treatment Naive HIV-1 Infected Patients with a Unique Pharmacokinetic Profile (10/28/08) Safety and Efficacy of Raltegravir-Based Versus Efavirenz-Based Combination Therapy in Treatment-Naive HIV-1 Infected Patients (10/28/08) 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients - BMS Press Release (10/28/08) Reanalysis of the MERIT Study with the Enhanced Trofile Assay (MERIT-ES) (10/28/08) Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naïve Adults, Tibotec press release (10/27/08) Efficacy and safety of darunavir/ritonavir 800/100mg once-daily versus lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients at 96 weeks: ARTEMIS (TMC114-C211) (10/27/08) Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG 5211 Results (10/27/08) ATRIPLA: Simplification of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir DF Single Tablet Regimen vs. Continued Unmodified Antiretroviral Therapy in Virologically-Suppressed, HIV-1-Infected Patients (10/27/08) ATRIPLA: The 48-Week Efficacy and Safety of Switching to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected Patients Receiving HAART (11/18/08) Atazanavir/Ritonavir vs Lopinavir/Ritonavir in Antiretroviral-Naïve HIV-1-Infected Patients: CASTLE 96 Week Efficacy and Safety (10/27/08) Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naïve, HIV-1 Infected, HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial (10/27/08) Effects of NRTI backbone on efficacy of first-line boosted PI based HAART: meta-analysis comparing TDF to ABC (10/27/08) Steady Evolution of Integrase Mutations After Raltegravir Fails - Written by Mark Mascolini - (10/27/08) Results on First-Line ABC/3TC With RNA Above 100,000: ARIES Study of abacavir/3TC plus atazanavir/r - Written by Mark Mascolini - (10/27/08) Independent Analysis Suggests TDF/FTC Outdoes ABC/3TC With First-Line PIs - Written by Mark Mascolini - (10/27/08) Enhanced Trofile Assays Shifts Results of ACTG 5211 Vicriviroc Trial - Written by Mark Mascolini - (10/27/08) First-Line Raltegravir Controls HIV as Well as Efavirenz for 48 Weeks - Written by Mark Mascolini - (10/27/08) Risk of Death 70% Higher When Delaying ART With CD4s at 351 to 500 - Written by Mark Mascolini - (10/27/08) Black Women in US Less Likely to Get Antiretrovirals, Regardless of Insurance - Written by Mark Mascolini - (10/27/08) In-Hospital Death Risk 4 Times Higher in Blacks Than Whites With HIV - Written by Mark Mascolini - (10/27/08) Frequent Sexual Activity by Brooklyn Teens Infected With HIV at Birth - Written by Mark Mascolini - (10/27/08) Greater Lipodystrophy Risk in Older US Children With Low Viral Load - Written by Mark Mascolini - (10/27/08) Half of Black US Women Switch HIV Clinicians Because of Communication Problems - Written by Mark Mascolini - (10/27/08)